Aurgalys Team
Selected Customers
Interim Management
Quantum Genomics [ALQGC]
Corporate Finance
Management Assistance
Due Diligence
Interim Management
Investor Assistance
Onxeo [ONXEO]
Diaxonhit [ALEHT]

.:: Intrasense [ALINS] ::.

Intrasense is a medical device company listed on Alternext Paris [ALINS], developping medical imaging software. The company’s lead product, Myrian, is a vendor-neutral software suite that can be used to analyze medical images acquired with any modality (MRI, CT Scan, X-Rays…). The company has already secured numerous multi-annual deals with leaders on the market, such as Toshiba, Cerner or Merge Healthcare (IBM). After difficult years in terms of sales performance in 2013 and 2014, the management has implemented a structuring plan that has put Intrasense back on track. The 2015 turnover was up 20%, while H1-2016 revenues were up 8% compared to the same period in 2015.

From Nov 22th, 2017, Aurgalys analyst reports on Intrasense will be published in English and French

A partir du 22 novembre 2017, les rapports d’analyse d’Aurgalys sur Intrasense seront publiés en Français et en Anglais

The coverage was initiated Feb 15th, 2017

Our target price for Intrasense as of Nov 22th, 2017, is €0.90/ share